Select all docs (Max 200)
Narrow Results:
Publication Year
Medical Subject
- Abstracts 1
- Adolescent 11
- Adult 15
- Aged 15
- Aged, 80 and over 5
- Age Distribution 2
- Age Factors 1
- Age of Onset 1
- Alaska 1
- Algorithms 1
- Analysis of Variance 1
- Anti-Bacterial Agents 2
- Antibiotic Prophylaxis 1
- Antifungal Agents 3
- Article 4
- Bacteremia 2
- Bacterial Infections 3
- Bacterial Outer Membrane Proteins 1
- Bacterial Typing Techniques 2
- Candida 3
- Candida glabrata 1
- Candidemia 5
- Capsular serotypes 1
- Carrier State 1
- Case-Control Studies 3
- Cdc—History 1
- CDI 1
- Child 13
- Child, Preschool 11
- Clone Cells 1
- Clostridioides difficile 3
- Clostridioides difficile infection 1
- Clostridium difficile 2
- Clostridium Infections 5
- Cohort Studies 3
- Coinfection 1
- Communicable Disease Control 3
- Communicable Diseases, Emerging 5
- Community-Acquired Infections 1
- Community Networks 1
- CoronaVirus Infections 2
- Cost of Illness 1
- COVID-19 3
- COVID-19 Vaccines 2
- Cross-Sectional Studies 1
- Cross Infection 2
- Culture Media 1
- Diabetes Complications 1
- Dispatch 1
- Drug Resistance, Bacterial 2
- Drug Resistance, Fungal 2
- Echinocandins 1
- Education 1
- Electrophoresis, Gel, Pulsed-Field 2
- Emerging Infections Program (EIP) 2
- Enterocolitis, Pseudomembranous 1
- Environmental Exposure 1
- Epidemiological Monitoring 3
- epidemiology 2
- Fasciitis, Necrotizing 1
- Female 19
- Fluconazole 1
- Fluoroquinolones 1
- Haemophilus Infections 4
- Haemophilus influenzae 6
- Hospitalization 3
- Humans 34
- Incidence 18
- Infant 16
- Infant, Newborn 7
- Influenza, Human 2
- Major Articles 5
- Male 16
- Meningococcal Infections 2
- Microbial Sensitivity Tests 3
- Middle Aged 13
- Neisseria meningitidis 2
- Pneumococcal Infections 4
- Pneumococcal Vaccines 5
- Population Surveillance 11
- Pregnancy 2
- Public Health 2
- Public Health Surveillance 3
- Research 2
- Retrospective Studies 3
- Risk Factors 6
- risk factors 2
- Serogroup 6
- Serotyping 7
- Sex Distribution 2
- Streptococcal Infections 6
- Streptococcus agalactiae 3
- Streptococcus pneumoniae 3
- Streptococcus pyogenes 3
- Treatment Outcome 4
- United States 11
- Vaccination 3
- Vaccines, Conjugate 4
- Vaccines, Synthetic 2
- Young Adult 8
Personal Author
Corporate Author
- Active Bacterial Core Surveillance Team of the Emerging Infections Program Network 1
- Adult Pneumococcal Carriage Study Group 1
- Atlanta Veterans Affairs Medical Center 1
- California Emerging Infections Program. 1
- CDC COVID-19 Response Team. 1
- Center for Surveillance, Epidemiology, and Laboratory Services (U.S.) 1
- Centers for Disease Control and Prevention (U.S.)Epidemic Intelligence Service. 1
- Clostridium difficile Infection Surveillance Investigators, Centers for Disease Control and Prevention 1
- Colorado. Department of Public Health and Environment. Connecticut Emerging Infections Program. 1
- Div. of Foodborne, Waterborne, and Environmental Diseases 1
- Div. of Scientific Education and Professional Development 1
- Emory University School of Medicine. 1
- Emory University School of Medicine Dept. of Medicine 1
- Epidemic Intelligence Service 1
- General Dynamics Information Technology. 1
- Georgia Emerging Infections Program. 2
- Johns Hopkins Bloomberg School of Public Health Maryland Emerging Infections Program 1
- Maryland. Department of Health. 1
- Michigan. Department of Health & Human Services. 1
- Minnesota. Department of Health. 1
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.) 1
- New Mexico Emerging Infections Program. 1
- New York State Department of Health. 1
- Ohio. Department of Health. 1
- Oregon Health Authority 1
- Oregon Health Authority. Public Health Division. 1
- Salt Lake County (Utah). Health Department. 1
- Stat-Epi Associates, Inc. 1
- United States. Advisory Committee on Immunization Practices. Pneumococcal Vaccines Work Group. 1
- University of California, Berkley. School of Public Health. 1
- University of Rochester. School of Medicine and Dentistry. 1
- Vanderbilt University Medical Center. 1
- Vanderbilt University School of Medicine 1
- Veterans Affairs Medical Center (Atlanta, Ga.) 1
- Yale School of Public Health, New Haven, Connecticut 1
Place as Subject
- Atlanta, GA 1
- Baltimore, MD 2
- California 1
- Colorado 1
- Connecticut 1
- Georgia 5
- Maryland 2
- Michigan 1
- Minnesota 1
- New Mexico 1
- New York 1
- Ohio 1
- Oregon 2
- Tennessee 2
- United States 16
- Utah 1
Resource Type General
Resource Type Specific
Keywords
- 13-valent pneumococcal conjugate vaccine 1
- American Indian and Alaska Native 1
- antimicrobial stewardship 1
- bacterial infections 1
- Chlorination 1
- clinical laboratory techniques 1
- clinical outcomes 1
- Clostridium difficile 3
- community-associated 1
- COVID-19 1
- diabetes 1
- epidemiology 4
- Fluoroquinolone 1
- group A Streptococcus infections 1
- Haemophilus influenzae 4
- Haemophilus influenzae vaccines 1
- Household water treatment 1
- incidence 1
- Indirect cohort 1
- invasive bacterial disease 1
- invasive disease 2
- Invasive pneumococcal disease 1
- mortality 1
- multivariable analysis 1
- NAP1/027 1
- nonpharmaceutical intervention 1
- nontypeable Haemophilus influenzae 1
- nucleic acid amplification techniques 1
- obesity 1
- Older adults 1
- PCV13 1
- pediatric 1
- Pneumococcal carriage 1
- Pneumococcal conjugate vaccine 1
- Pneumococcal infections 1
- Safe water storage 1
- serotype a 1
- strain typing 1
- Streptococcus pneumonia 1
- Streptococcus pneumoniae 1
- surveillance 3
- United States 2
- Vaccine effectiveness 1
Select all docs (Max 200)
1 -
20 of 47 Results
SELECT A RANGE
SELECT A FORMAT
Refine Results
Refine Results:
- Abstracts (1)
- Adolescent (11)
- Adult (15)
- Aged (15)
- Aged, 80 and over (5)
- Age Distribution (2)
- Age Factors (1)
- Age of Onset (1)
- Alaska (1)
- Algorithms (1)
- Analysis of Variance (1)
- Anti-Bacterial Agents (2)
- Antibiotic Prophylaxis (1)
- Antifungal Agents (3)
- Article (4)
- Bacteremia (2)
- Bacterial Infections (3)
- Bacterial Outer Membrane Proteins (1)
- Bacterial Typing Techniques (2)
- Candida (3)
- Candida glabrata (1)
- Candidemia (5)
- Capsular serotypes (1)
- Carrier State (1)
- Case-Control Studies (3)
- Cdc—History (1)
- CDI (1)
- Child (13)
- Child, Preschool (11)
- Clone Cells (1)
- Clostridioides difficile (3)
- Clostridioides difficile infection (1)
- Clostridium difficile (2)
- Clostridium Infections (5)
- Cohort Studies (3)
- Coinfection (1)
- Communicable Disease Control (3)
- Communicable Diseases, Emerging (5)
- Community-Acquired Infections (1)
- Community Networks (1)
- CoronaVirus Infections (2)
- Cost of Illness (1)
- COVID-19 (3)
- COVID-19 Vaccines (2)
- Cross-Sectional Studies (1)
- Cross Infection (2)
- Culture Media (1)
- Diabetes Complications (1)
- Dispatch (1)
- Drug Resistance, Bacterial (2)
- Drug Resistance, Fungal (2)
- Echinocandins (1)
- Education (1)
- Electrophoresis, Gel, Pulsed-Field (2)
- Emerging Infections Program (EIP) (2)
- Enterocolitis, Pseudomembranous (1)
- Environmental Exposure (1)
- Epidemiological Monitoring (3)
- epidemiology (2)
- Fasciitis, Necrotizing (1)
- Female (19)
- Fluconazole (1)
- Fluoroquinolones (1)
- Haemophilus Infections (4)
- Haemophilus influenzae (6)
- Hospitalization (3)
- Humans (34)
- Incidence (18)
- Infant (16)
- Infant, Newborn (7)
- Influenza, Human (2)
- Major Articles (5)
- Male (16)
- Meningococcal Infections (2)
- Microbial Sensitivity Tests (3)
- Middle Aged (13)
- Neisseria meningitidis (2)
- Pneumococcal Infections (4)
- Pneumococcal Vaccines (5)
- Population Surveillance (11)
- Pregnancy (2)
- Public Health (2)
- Public Health Surveillance (3)
- Research (2)
- Retrospective Studies (3)
- Risk Factors (6)
- risk factors (2)
- Serogroup (6)
- Serotyping (7)
- Sex Distribution (2)
- Streptococcal Infections (6)
- Streptococcus agalactiae (3)
- Streptococcus pneumoniae (3)
- Streptococcus pyogenes (3)
- Treatment Outcome (4)
- United States (11)
- Vaccination (3)
- Vaccines, Conjugate (4)
- Vaccines, Synthetic (2)
- Young Adult (8)
- Active Bacterial Core Surveillance Team of the Emerging Infections Program Network (1)
- Adult Pneumococcal Carriage Study Group (1)
- Atlanta Veterans Affairs Medical Center (1)
- California Emerging Infections Program. (1)
- CDC COVID-19 Response Team. (1)
- Center for Surveillance, Epidemiology, and Laboratory Services (U.S.) (1)
- Centers for Disease Control and Prevention (U.S.)Epidemic Intelligence Service. (1)
- Clostridium difficile Infection Surveillance Investigators, Centers for Disease Control and Prevention (1)
- Colorado. Department of Public Health and Environment. Connecticut Emerging Infections Program. (1)
- Div. of Foodborne, Waterborne, and Environmental Diseases (1)
- Div. of Scientific Education and Professional Development (1)
- Emory University School of Medicine. (1)
- Emory University School of Medicine Dept. of Medicine (1)
- Epidemic Intelligence Service (1)
- General Dynamics Information Technology. (1)
- Georgia Emerging Infections Program. (2)
- Johns Hopkins Bloomberg School of Public Health Maryland Emerging Infections Program (1)
- Maryland. Department of Health. (1)
- Michigan. Department of Health & Human Services. (1)
- Minnesota. Department of Health. (1)
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.) (1)
- New Mexico Emerging Infections Program. (1)
- New York State Department of Health. (1)
- Ohio. Department of Health. (1)
- Oregon Health Authority (1)
- Oregon Health Authority. Public Health Division. (1)
- Salt Lake County (Utah). Health Department. (1)
- Stat-Epi Associates, Inc. (1)
- United States. Advisory Committee on Immunization Practices. Pneumococcal Vaccines Work Group. (1)
- University of California, Berkley. School of Public Health. (1)
- University of Rochester. School of Medicine and Dentistry. (1)
- Vanderbilt University Medical Center. (1)
- Vanderbilt University School of Medicine (1)
- Veterans Affairs Medical Center (Atlanta, Ga.) (1)
- Yale School of Public Health, New Haven, Connecticut (1)
- 13-valent pneumococcal conjugate vaccine (1)
- American Indian and Alaska Native (1)
- antimicrobial stewardship (1)
- bacterial infections (1)
- Chlorination (1)
- clinical laboratory techniques (1)
- clinical outcomes (1)
- Clostridium difficile (3)
- community-associated (1)
- COVID-19 (1)
- diabetes (1)
- epidemiology (4)
- Fluoroquinolone (1)
- group A Streptococcus infections (1)
- Haemophilus influenzae (4)
- Haemophilus influenzae vaccines (1)
- Household water treatment (1)
- incidence (1)
- Indirect cohort (1)
- invasive bacterial disease (1)
- invasive disease (2)
- Invasive pneumococcal disease (1)
- mortality (1)
- multivariable analysis (1)
- NAP1/027 (1)
- nonpharmaceutical intervention (1)
- nontypeable Haemophilus influenzae (1)
- nucleic acid amplification techniques (1)
- obesity (1)
- Older adults (1)
- PCV13 (1)
- pediatric (1)
- Pneumococcal carriage (1)
- Pneumococcal conjugate vaccine (1)
- Pneumococcal infections (1)
- Safe water storage (1)
- serotype a (1)
- strain typing (1)
- Streptococcus pneumonia (1)
- Streptococcus pneumoniae (1)
- surveillance (3)
- United States (2)
- Vaccine effectiveness (1)
- :Pimenta, Fabiana ;Gertz, Robert E.January 08 2019 | Front Microbiol. 2019; 9:is a highly impactful bacterial pathogen on a global scale. The principal pneumococcal virulence factor and target of effective vaccines is its polysa...
- :Wiringa, Ann E. ;Shutt, Kathleen A.Dec 12 2013 | PLoS One. 2013; 8(12).:BackgroundThe detection of meningococcal outbreaks relies on serogrouping and epidemiologic definitions. Advances in molecular epidemiology have impro...
- :Moore, Matthew R. ;Link-Gelles, RuthFeb 03 2015 | Lancet Infect Dis. 15(3):301-309.:BackgroundIn 2000, 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in the U.S. and resulted in dramatic reductions in invasive pneumococ...
- :Harris, Christine M. ;Wu, Henry M.Dec 20 2016 | Open Forum Infect Dis. 2016; 3(4).:Background.Although human immunodeficiency virus (HIV) infection is an established risk factor for several bacterial infections, the association betwe...
- :MacNeil, Jessica R. ;Bennett, NancyJanuary 12 2015 | Pediatrics. 135(2):e305-e311:BACKGROUNDThe incidence of meningococcal disease is currently at historic lows in the United States; however, incidence remains highest among infants ...
- :Dharan, Nila J. ;Sokolow, Leslie Z.Jun 2014 | Pediatr Infect Dis J. 2014; 33(6):e141-e150.:Background:Young children are at increased risk of severe outcomes from influenza illness, including hospitalization. We conducted a case-control stud...
- :Tsay, Sharon ;Benedict, KaitlinOct 04 2017 | Open Forum Infect Dis. 2017; 4(Suppl 1):S55.:BackgroundCandidemia and Clostridium difficile infection (CDI) are two common healthcare-associated infections (HAIs) and share risk factors such as a...
- :Kobayashi, Miwako ;Matanock, Almea5 01 2022 | J Acquir Immune Defic Syndr. 90(1):6-14:People with HIV (PWH) are at increased risk for invasive pneumococcal disease (IPD). Thirteen-valent pneumococcal conjugate vaccine (PCV13) was recomm...
- :Hunter, Jennifer C. ;Mu, YiJan 18 2016 | Open Forum Infect Dis. 2016; 3(1).:Background. Approximately 4 million Americans receive nursing home (NH) care annually. Nursing home residents commonly have risk factors for Clostr...
- :Vallabhaneni, Snigdha ;Cleveland, Angela A.Dec 14 2015 | Open Forum Infect Dis. 2015; 2(4).:Background. Echinocandins are first-line treatment for Candida glabrata candidemia. Echinocandin resistance is concerning due to limited remaining ...
- :Dantes, Raymund ;Mu, YiAug 11 2015 | Open Forum Infect Dis. 2015; 2(3).:Background. Antibiotic use predisposes patients to Clostridium difficile infections (CDI), and approximately 32% of these infections are community-...
- :Blain, Amy ;MacNeil, JessicaJul 03 2014 | Open Forum Infect Dis. 2014; 1(2).:Background Since the introduction of the Haemophilus influenzae serotype b vaccine, H influenzae epidemiology has shifted. In the United States, the...
- :Lessa, Fernanda C. ;Mu, YiJul 28 2014 | Open Forum Infect Dis. 2014; 1(2).:Background Clostridium difficile infection (CDI) is no longer restricted to hospital settings, and population-based incidence measures are needed. U...
- :Lessa, Fernanda C. ;Mu, Yi2 26 2015 | N Engl J Med. 372(9):825-834:backgroundThe magnitude and scope of Clostridium difficile infection in the United States continue to evolve.methodsIn 2011, we performed active popul...
- :McGee, Lesley ;Chochua, Sopio3 15 2021 | Clin Infect Dis. 72(6):1004-1013:Background:Group B Streptococcus (GBS) is a leading cause of neonatal sepsis and meningitis and an important cause of invasive infections in pregnant ...
- :Zhou, Hong ;Haber, MichaelFeb 2012 | Emerg Infect Dis. 18(2):294-297.:To confirm whether respiratory virus infections increase susceptibility to invasive pneumococcal pneumonia, we examined data from 11 influenza seasons...
- :Factor, Stephanie H. ;Levine, Orin S.Aug 2003 | Emerg Infect Dis. 9(8):970-977:We conducted a case-control study to identify risk factors for invasive group A streptococcal (GAS) infections, which can be fatal. Case-patients were...
- :Millman, Alexander J. ;Reed, CarrieSep 2015 | Emerg Infect Dis. 21(9):1595-1601:Diagnostic test sensitivity affects rate estimates for laboratory-confirmed influenza-associated hospitalizations. We used data from FluSurv-NET, a na...
- :Langley, Gayle ;Schaffner, WilliamSep 2015 | Emerg Infect Dis. 21(9):1520-1528:Active Bacterial Core surveillance (ABCs) was established in 1995 as part of the Centers for Disease Control and Prevention Emerging Infections Progra...
- :Schuchat, Anne ;Hilger, Tami2001 Jan-Feb | Emerg Infect Dis. 7(1):92-99.:Active Bacterial Core surveillance (ABCs) is a collaboration between the Centers for Disease Control and Prevention and several state health departmen...
Exit Notification/Disclaimer Policy
Links with this icon indicate that you are leaving the CDC website.
- The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
- Linking to a non-federal Website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
- You will be subject to the destination website's privacy policy when you follow the link.
- CDC is not responsible for Section 508 compliance (accessibility) on other federal or private websites.